GlycoMimetics (GLYC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

On Thursday, shares of biotech company GlycoMimetics Inc. (GLYC) are skyrocketing, up over 100% to $10.92 per share in afternoon trading after the company announced that the FDA designated one of ...

Is GlycoMimetics (GLYC) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out. GlycoMimetics is one of 1185 companies in the Medical group.

GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders October 29, 2024 08:22 AM Eastern Daylight Time ...

StockNews.com initiated coverage on shares of GlycoMimetics (NASDAQ:GLYC – Free Report) in a report issued on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock.

Average portfolio weight of all funds dedicated to GLYC is 0.01%, an increase of 679.56%. Total shares owned by institutions increased in the last three months by 72.63% to 30,952K shares.

GLYC stock opened at $0.18 on Monday. GlycoMimetics has a twelve month low of $0.14 and a twelve month high of $2.81.

GLYC could be susceptible to more downgrades, too, with six "strong buy" ratings on the table. Even before today's plummet, GLYC had been having some trouble on the charts.